Therapist Psychedelic Experience: Participant Preferences in US Psilocybin Trials

Participants in US Psilocybin Trial Prefer Therapists With Personal Experience

Frontline healthcare workers participating in a 2023–2024 randomized controlled trial (ClinicalTrials.gov Identifier: NCT05557643) for psilocybin-assisted psychotherapy (PAP) reported a clear preference for therapists and study teams with personal psychedelic experience. This preference was observed regardless of whether participants themselves had prior psychedelic exposure, suggesting a generalized expectation or trust factor regarding therapist background in this context.

The study enrolled 25 physicians and nurses experiencing depression and burnout related to the COVID-19 pandemic. Participants were randomized to either an 8-week mindfulness-based stress reduction (MBSR) program alone or MBSR plus group PAP with a 25 mg dose of psilocybin. While primary clinical outcomes have been published separately, the present analysis focuses on participant attitudes toward the relevance of therapist and study team personal psychedelic experience.

Mechanisms: Trust, Empathy, and Therapeutic Alliance

Participant preference for therapists with personal psychedelic experience may reflect perceived empathy, credibility, or an expectation of shared understanding during PAP. In the context of psychedelic therapy—where altered states, vulnerability, and existential themes are common—participants may believe that therapists who have themselves undergone similar experiences are better equipped to provide support and guidance.

This dynamic is not unique to psychedelics; in other therapeutic modalities, shared lived experience can foster trust and rapport. However, the intensity and unfamiliarity of psychedelic states may amplify the perceived importance of therapist firsthand knowledge. Notably, the study found that this preference was independent of whether participants themselves had used psychedelics, indicating that the expectation is not limited to those with prior experience.

Policy and Research Implications: Hiring, Training, and Disclosure

The finding that participants prefer therapists with personal psychedelic experience has immediate implications for hiring, training, and disclosure practices in both research and clinical settings. Institutions and trial sponsors may face pressure to recruit or prioritize therapists with such experience, potentially influencing the composition of study teams and the generalizability of trial results.

• Hiring: Should personal psychedelic experience become an explicit or implicit criterion for therapist selection in clinical trials or clinical practice?
• Training: Some training programs already include non-therapeutic psychedelic experiences for clinicians, but these are not universally available or accepted. The study's findings may increase demand for such programs, but also raise questions about equity and standardization.
• Disclosure: Whether and how therapists disclose their personal experience to participants is ethically complex. Transparency may build trust but could also introduce bias or influence expectations.

Importantly, the US Food and Drug Administration (FDA) and institutional review boards (IRBs) have not issued specific guidance on this issue, leaving research teams to navigate these questions independently. This lack of standardization could affect trial reproducibility and the development of evidence-based best practices.

Risks, Bias, and Unintended Consequences

Prioritizing therapists with personal psychedelic experience introduces potential risks and sources of bias in both research and clinical care. Therapists with such backgrounds may unintentionally project their own frameworks or expectations onto participants, subtly shaping outcomes or the therapeutic process. This could confound trial results, especially when comparing interventions or evaluating the generalizability of findings to broader populations.

There is also a risk of creating a two-tiered workforce, where those without personal experience are seen as less qualified, regardless of clinical skill or training. This could limit diversity in the field and create barriers for clinicians from backgrounds or jurisdictions where psychedelic use is inaccessible or legally risky. A less discussed but concrete failure mode is the possibility that therapists with personal experience may over-identify with participants, blurring professional boundaries and complicating supervision or adverse event management.

Looking Forward: Standardization and Transparency in Psychedelic Trials

The preference for therapists with personal psychedelic experience is now an empirically documented factor in participant expectations, but it remains unclear how this should be operationalized in research or clinical settings. Future trials may need to explicitly document therapist backgrounds and consider stratification or disclosure practices as part of study design. Regulatory agencies and professional organizations will likely need to develop clearer guidance on training, disclosure, and the management of potential bias as psychedelic therapies move toward broader clinical adoption.

For now, research teams should balance participant preferences with rigorous monitoring of bias and a commitment to equity and transparency. As the field matures, ongoing empirical work—such as comparative trials assessing therapist experience as a moderator of outcomes—will be essential to inform ethical and effective practice.

How we research: This article was written by Dr. Alex M. Carter, PhD (clinical psychology, psychedelic trial methodology). Reviewed by Dr. Jamie Lee, MD on 2026-10-02. Primary data and trial protocol sourced from OpenAlex and ClinicalTrials.gov NCT05557643.